AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2004 DEC 2 - (NewsRx.com & NewsRx.net) -- A new study of the affect of depot medroxyprogesterone acetate on bone mineral density confirms findings of some previous studies and refutes others.
"Previous studies of the injectable contraceptive depot medroxyprogesterone acetate (DMPA, Depo-Provera) and bone mineral density have produced differing results; a bone mineral deficit has been demonstrated in studies of the lumbar spine and hip, but not in studies of the forearm. In addition, DMPA users are likely to be smokers, pregnant at a young age, and not educated beyond high school level, which could contribute to the observed bone density deficit," suggested J.S. Walsh and colleagues at the University of Sheffield, U.K.
In their study, bone mineral density (BMD) was measured at the spine, hip, and forearm, and the effect of social and lifestyle factors was removed by using individually matched controls.
The researchers "recruited 50 pairs of women ages 18 to 25 from Sheffield general practices and family planning clinics. DMPA use was of at least 12 months duration (mean 37 months), and commenced before the age of 20. Controls were matched for source of recruitment, postcode, age, height, body mass index, ...
Source: HighBeam Research, DMPA use associated with bone density deficit in young adult women.